Clinical Trial Update: AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated AMG-386 in combination with either pegylated liposomal doxorubicin or topotecan in advanced recurrent epithelial ovarian cancer. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• AMG-386 (trebananib)
• Pegylated liposomal doxorubicin (Doxil) (liposomal doxorubicin)
• Topotecan (Hycamtin) (Topotecan)

Snippet

Sponsor: Amgen | Conditions: Cancer, Carcinoma | Phase 1 | Status: COMPLETED